Co-crystal structures of inhibitors with MRCKβ, a key regulator of tumor cell invasion

Heikkila, T. et al. (2011) Co-crystal structures of inhibitors with MRCKβ, a key regulator of tumor cell invasion. PLoS ONE, 6(9), e24825. (doi: 10.1371/journal.pone.0024825)

[img] Text
56824.pdf
Available under License Creative Commons Attribution.

1MB

Publisher's URL: http://dx.doi.org/10.1371/journal.pone.0024825

Abstract

MRCK alpha and MRCK beta (myotonic dystrophy kinase-related Cdc42-binding kinases) belong to a subfamily of Rho GTPase activated serine/threonine kinases within the AGC-family that regulate the actomyosin cytoskeleton. Reflecting their roles in myosin light chain (MLC) phosphorylation, MRCK alpha and MRCK beta influence cell shape and motility. We report further evidence for MRCK alpha and MRCK beta contributions to the invasion of cancer cells in 3-dimensional matrix invasion assays. In particular, our results indicate that the combined inhibition of MRCK alpha and MRCK beta together with inhibition of ROCK kinases results in significantly greater effects on reducing cancer cell invasion than blocking either MRCK or ROCK kinases alone. To probe the kinase ligand pocket, we screened 159 kinase inhibitors in an in vitro MRCK beta kinase assay and found 11 compounds that inhibited enzyme activity >80% at 3 mu M. Further analysis of three hits, Y-27632, Fasudil and TPCA-1, revealed low micromolar IC(50) values for MRCK alpha and MRCK beta. We also describe the crystal structure of MRCK beta in complex with inhibitors Fasudil and TPCA-1 bound to the active site of the kinase. These high-resolution structures reveal a highly conserved AGC kinase fold in a typical dimeric arrangement. The kinase domain is in an active conformation with a fully-ordered and correctly positioned alpha C helix and catalytic residues in a conformation competent for catalysis. Together, these results provide further validation for MRCK involvement in regulation of cancer cell invasion and present a valuable starting point for future structure-based drug discovery efforts.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Olson, Professor Michael
Authors: Heikkila, T., Wheatley, E., Crighton, D., Schroder, E., Boakes, A., Kaye, S.J., Mezna, M., Pang, L., Rushbrooke, M., Turnbull, A., and Olson, M.F.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:PLoS ONE
Publisher:Public Library of Science
ISSN:1932-6203
ISSN (Online):1932-6203
Published Online:20 September 2011
Copyright Holders:Copyright © 2011 The Authors
First Published:First published in PLoS ONE 6(9):e24825
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record